INTRODUCTION
β-Hemoglobinopathies, including sickle cell disease (SCD) and β-thalassemia (β-thal), are inherited disorders caused by mutations in the β-globin gene. These conditions result in dysfunctional or decreased β-globin protein, thereby causing severe anemia, organ damage, and reduced life expectancy. [1] [2] [3] [4] A promising therapeutic option with proven efficacy is the pharmacologic induction of fetal hemoglobin (HbF). This strategy developed from the observation that β-hemoglobinopathy patients with high levels of HbF have milder clinical disorders. 5, 6 This revealed γ-globin to be a suitable replacement for mutated or absent
RESULTS

Salubrinal activates the ISR pathway in K562 cells
To begin testing our hypothesis, we used a known pharmacologic activator of the ISR pathway, salubrinal (Sal). We chose Sal because it has been previously shown to inhibit the important negative feedback loop that regulates dephosphorylation of p-eIF2α, 32 thus increasing p-eIF2α without exposure to harmful cell stresses. Normally under stress conditions, eIF2α is phorphorylated, global translation is inhibited, but a few transcripts are selectively translated ( Figure 1A) . A well-characterized example is the selective translation of ATF4 via multiple upstream open reading frames located in its 5'-untranslated region. 33, 34 ATF4 is a transcription factor that upregulates many stress response genes, including ATF3, CHOP, and GADD34.
GADD34 protein, acting as a chaperone, then binds to protein phosphatase 1 (PP1) and targets it to dephosphorylate p-eIF2α and decrease the stress response. 35 Another chaperone, CReP, also targets PP1 to dephosphorylate p-eIF2α, but is constitutively present in the cell and does not require stress to be induced. 36 Sal reduces the negative regulation of this pathway by inhibiting the ability of GADD34-and CReP-PP1 complexes to dephosphorylate p-eIF2α.
We first performed a dose response of Sal in the K562 erythroleukemia cell line to identify its lowest doses that enhanced p-eIF2α levels and downstream ISR signaling. Within 6
hours, 3 and 6 μM Sal increased p-eIF2α to a similar extent as our positive control, an ER stress inducer thapsigargin ( Figure 1B) . Correspondingly, Sal also enhanced ATF4 and GADD34 protein ( Figure 1C) , as well as mRNA expression of ATF3 and CHOP in a dosedependent manner ( Figure 1D ). These results identified doses of Sal that are capable of increasing p-eIF2α to an extent that activates ISR signaling.
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Salubrinal increases p-eIF2α and inhibits translation initiation in human primary erythroid progenitors
In order to adequately test the ISR pathway in a physiologically relevant context containing both HbF and HbA, we used a previously described 2-phase in vitro erythroid differentiation system. 26 G-CSF-mobilized CD34 + peripheral blood cells were expanded for a week in culture, and on day 7, EPO was added to the medium to facilitate erythroid differentiation through day 20. Our first objective was to verify that 3 and 6 μM Sal could increase p-eIF2α in these cells. Indeed, Sal enhanced p-eIF2α levels within a 12-hour timecourse when treated on day 15 of culture ( Figure 2A ). Although this increase was not as dramatic as seen in K562 cells, it is important to note that phosphorylation of only 20-30% of eIF2α is needed to completely inhibit protein synthesis. 37, 38 Next, we analyzed downstream ISR signaling and were surprised to find that Sal did not increase ATF4 or GADD34 protein ( Figure   2A ). In fact, 6 μM Sal slightly reduced ATF4 at 12 hours after treatment compared to the untreated control. In line with these data, there was no increase in ATF3 or CHOP gene expression when analyzed within 6 hours ( Figure 2B ) or during the entire differentiation period ( Figure 2C ).
Since Sal failed to activate canonical downstream ISR gene expression, we used polysome profiling to determine if the increased p-eIF2α was affecting translation. This technique can determine if protein translation is decreased, as indicated by a shift in mRNA from the polysome to monosome fractions when translation initiation is inhibited. 39 When primary erythroid progenitors were treated with Sal for 6 hours, polysome-associated mRNA was reduced coincident with an increased 80S monosome peak ( Figure 2D ). Taken together, these data indicate that Sal increases p-eIF2α to an extent that is sufficient to repress translation initiation.
Salubrinal increases HbF via a post-transcriptional mechanism
Next, we optimized a Sal dosing schedule to evaluate its effects on globin production.
We found that Sal treatments on day 15 and 18 of culture were well tolerated and did not change the differentiation profile (Figures 3A-C) or alter cellular proliferation ( Figure 3D ). To confirm that these effects were not due to time of treatment, cells were also treated on day 9 and 12 and no differences were found in cell proliferation or differentiation (Figures S1A-B) . This is an important point, as changes in growth and differentiation could alter HbF production independent of changes in p-eIF2α.
We then analyzed γ-and β-globin gene expression throughout differentiation. Treatment with either 3 or 6 μM Sal on day 15 and 18 did not significantly change γ-or β-globin mRNA expression relative to the untreated control ( Figure 3E) . We also compared the area under the curve (AUC) of the globin mRNA levels, which is calculated from days 7 to 20 for γ and β-globin ( Figure 3F ) and compared as a γ/(γ+β) ratio ( Figure 3G) . The AUC estimates the total amount of mRNA for each gene that is available for translation throughout the differentiation period. We found that Sal treatment did not change the γ/(γ+β) ratio, confirming that Sal did not change globin mRNA expression. To ensure this result was not due to treating late in erythropoiesis, cells were treated with Sal on days 9 and 12, which also did not change γ-or β-globin mRNA levels ( Figure S1C-D) .
In contrast to the transcript expression, 3 and 6 μM Sal dose dependently increased the percent of HbF (Figures 4A-B differentially or reciprocally regulated at the translational level. Sal treatments earlier in the differentiation process before considerable amounts of hemoglobin are synthesized failed to significantly increase HbF, further supporting this conclusion ( Figure S1E ). Additionally, we wanted to ensure total hemoglobin levels were not dramatically decreased since we previously confirmed that Sal reduced global protein synthesis. We found that while there was a trend for Sal treatment to slightly reduce total hemoglobin content by 16.8%, these results were not significantly different from the untreated control across 5 independent experiments ( Figure 4C ).
Complementary pharmacologic and genetic approaches to ISR activation confirm involvement of p-eIF2α in post-transcriptional HbF induction mechanism
To further test whether increased p-eIF2α enhances HbF production posttranscriptionally, we assessed other pharmacologic agents that target the ISR pathway. We chose two compounds that have been shown to increase p-eIF2α through unique mechanisms.
BTdCPU (BT) was discovered in a chemical genetics screen to increase p-eIF2α by directly activating the HRI kinase, 40 the critical eIF2 kinase in erythroid cells. Guanabenz (GBZ) is an anti-hypertensive agent that was recently found to disrupt the association of GADD34 and PP1
to sustain p-eIF2α, attenuate protein translation, and restore protein homeostasis in stressed cells. 41 We treated differentiating primary erythroid precursors with 5 μM BT and 25 μM GBZ on days 15 and 18. Similarly to Sal, BT and GBZ did not change the γ/(γ+β) ratio of globin mRNA expression ( Figure 5A ), but did result in a 2-fold increase in the percent HbF on day 20 ( Figure   5B ). BT also increased the absolute levels of HbF like Sal, but GBZ failed to do so, indicating that this drug primarily reduced HbA ( Figure S2B ).
Since pharmacologic tools can have off-target effects especially at higher concentrations, we sought to substantiate our results with genetic modulation of the pathway.
We used short-hairpin (sh)RNAs targeting GADD34 and CReP to determine if increased p-
eIF2α was sufficient to induce HbF without increasing the γ/(γ+β) mRNA ratio. Primary erythroid progenitors were infected with virus containing a control or gene targeting shRNA on days 12
and 13 of culture. We achieved an average of 85-90% infection efficiency ( Figure S3A-B) eliminating the need for further manipulation of the cells via antibiotic selection or cell sorting.
We first confirmed gene knockdown by analyzing the mRNA percent remaining relative to the shRNA control on day 16 and found that both shRNAs targeting GADD34 and CReP caused about 50% knockdown ( Figure 5C ). GADD34 and CReP protein analyzed by western blotting at the same timepoint revealed a much greater degree of knockdown ( Figure 5D ). This suggests that reducing GADD34 and CReP inhibited protein synthesis, which contributed to the enhanced protein knockdown observed. Importantly, we then confirmed that GADD34 and CReP knockdown significantly increased p-eIF2α relative to the shRNA control on days 16 and 18
( Figure 5E ). We also found that reducing GADD34 and CReP in these cells did not increase canonical downstream ISR signaling, similar to the effects observed with Sal treatment ( Figure   S4A ).
Next, we analyzed the effects of GADD34 and CReP knockdown on globin production.
Consistent knockdown of these proteins over many days resulted in reduced mRNA expression of both γ-and β-globin ( Figure S4B ), which was not previously observed with Sal treatment.
However, this reduction was proportional so that neither GADD34 nor CReP knockdown changed the γ/(γ+β) mRNA ratio relative to the shRNA control during differentiation ( Figure 5F ).
We then evaluated HbF production using HPLC and found that both GADD34 and CReP knockdown caused a 2.5-fold increase in the percent HbF ( Figure 5G ). These results confirm that increasing p-eIF2α is sufficient to post-transcriptionally upregulate HbF in primary erythroid cells.
Combining salubrinal with activators of γ-globin transcription enhances HbF induction
Since Sal increases HbF production post-transcriptionally, we tested whether this unique mechanism of induction could enhance the HbF induction by clinically relevant compounds that increase γ-globin mRNA levels. We chose to use AZA since it is an effective and robust inducer of γ-globin gene expression in both SCD 11 and β-thal 12 patients and HU because it is the FDAapproved drug for SCD, although it produces a more modest increase in HbF. 
DISCUSSION
SCD and β-thal continue to cause significant morbidity and mortality on a global scale.
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Since a large proportion of hemoglobinopathy patients reside in countries that lack advanced facilities for diagnosis and management of these diseases, 44 these patients require improved
treatments that are safe and attainable worldwide. Considering these constraints, our goal has been to develop novel strategies to induce HbF pharmacologically, which have the greatest potential to be inexpensive and effective therapies. While most previous studies have focused on increasing γ-globin gene expression as an approach to induce HbF, there is also evidence that HbF may be post-transcriptionally regulated. [16] [17] [18] [19] However, no molecular pathway has been previously implicated in this mode of regulation. Therefore, we chose to focus on better understanding this level of HbF production with the intention of discovering new pharmacologic targets.
In this study, we show that increasing p-eIF2α can differentially regulate HbF and HbA post-transcriptionally. We used Sal, an inhibitor of eIF2α dephosphorylation, as a tool compound to increase p-eIF2α in human primary erythroid cells. Sal did not alter cell growth or differentiation in our in vitro system when treated early or late in the differentiation process. We found that Sal did not significantly change γ-or β-globin mRNA expression but dosedependently increased the percent HbF, revealing a post-transcriptional HbF induction mechanism. We further supported these findings by testing other ISR pathway activating agents, BT and GBZ, and by genetically reducing GADD34 and CReP expression. These results combined confirm the involvement of p-eIF2α in the induction of HbF.
A surprising result was the lack of robust downstream pathway activation despite elevated p-eIF2α produced by Sal treatment and our knockdown studies. A plausible explanation for this finding is that the ISR pathway is already activated during erythroid differentiation as previously shown in the murine system. 45 It is also known that ATF4 is a short- 48 These results probably reflect reduced protein translation to an extent that eIF2 can no longer be recycled for more rounds of translation initiation. Even proteins that are selectively translated when the concentration of ternary complex is low will stop being translated eventually.
Our results also revealed differences in the degree of eIF2α phosphorylation and how this affected globin mRNA expression. Although both Sal treatment and shRNA studies did not change the γ/(γ+β) mRNA ratio, GADD34 and CReP knockdown reduced total globin mRNA expression whereas Sal did not. This difference was probably due to the dramatic increase in peIF2α evident with knockdown of GADD34 and CReP relative to the more subtle changes in peIF2α elicited by Sal treatment. These results highlight an important feature of the p-eIF2α
pathway. Slight activation is beneficial since temporarily reducing translation allows the cell to save energy, selectively translate proteins to mediate cell survival, and restore homeostasis.
49
In the presence of more intense cell stress, translation is decreased to such an extent that this adaptive cell response is tipped to cell destruction and eventual apoptosis. Although we use GADD34 and CReP knockdown in this study to illustrate the involvement of p-eIF2α in the posttranscriptional induction of HbF, the chronic stress of removing these two important proteins is ultimately detrimental and globin expression is reduced. In contrast, pharmacologically perturbing this pathway with Sal was able to induce HbF and increase p-eIF2α to an extent that was well tolerated. This suggests that targeting this pathway therapeutically could be achievable.
For
Our findings and previous reports provide good rationale for increasing p-eIF2α with Sal, or a similar agent, to treat β-hemoglobinopathy patients. Recently, Suragani et al. found that treating erythroid precursors from β-thal mice with Sal augmented p-eIF2α, reduced globin translation, and decreased the accumulation of insoluble α-globin that causes oxidative stress and apoptosis. 45 Our current work revealed another potential therapeutic benefit of increasing peIF2α since it also caused induction of HbF. Elevated HbF could reduce the globin chain imbalance while simultaneously producing functional hemoglobin to alleviate the anemia in β-thal. Moreover, we found that Sal reduced HbA while increasing HbF, which could be applied to decrease the amount of mutated β-chain and reduce hemoglobin polymerization in SCD.
Although pharmacokinetic studies have been performed in mouse models with Sal, 48 more work will be required to find a suitable agent that is more potent and displays enhanced solubility in order to achieve clinical applicability.
Most importantly, we found that increasing p-eIF2α caused HbF to be induced through a post-transcriptional mechanism. Although the exact post-transcriptional mechanism is yet to be determined, we are actively investigating possibilities to explain these results. It is unlikely that differences in globin mRNA stability can explain the increased HbF since Sal did not change γ-or β-globin steady state mRNA levels. It is more likely that mRNA cellular location and resulting access to the translation machinery or differences in globin mRNA translation efficiency could explain our reported findings. Additionally, enhanced p-eIF2α has been shown to increase the protein chaperone reserve in the cell to assist protein folding during stress. 50 It is also possible that γ-and β-globin protein stability may be different in a dynamically changing protein environment especially if assisted by different protein chaperones.
In conclusion, we found that increasing eIF2α phosphorylation, by three unique pharmacologic agents and shRNA targeting two independent proteins, caused an increase in
HbF. This revealed for the first time a connection between p-eIF2α and a post-transcriptional (E) γ-globin and β-globin mRNA expression was evaluated over the course of differentiation from day 7 through 20. 3 μM and 6 μM Sal treatments occurred on day 15 and 18, and the fold increase relative to the untreated control day 7 sample is shown. No significant changes in γ-globin or β-globin mRNA levels are observed. Error bars represent ± SEM of three independent experiments (two different donors).
(F) The area under the curve (AUC) was calculated for γ-globin and β-globin mRNA expression from day 7 through 20. This representation of the data allows quantification of the total mRNA from each gene available for translation over the course of erythroid differentiation. 3 μM and 6 μM Sal treatments on days 15 and 18 did not change the γ-globin or β-globin AUC relative to the untreated control. Error bars represent ± SEM of three independent experiments (two different donors).
(G) The AUCs for γ-globin and β-globin were compared as a γ/(γ+β) ratio. 3 μM and 6 μM Sal did not change this ratio relative to the untreated control in three independent experiments using two unique donors. Error bars denote ± SEM. (B) The percent of HbF was quantified in five independent experiments (three different donors) comparing 3 μM and 6 μM Sal treatments to an untreated control. Sal dose-dependently increases the percent HbF. Error bars express ± SEM and P values were calculated using an unpaired two-tailed t-test.
(C) Equal numbers of cells were lysed on day 20 and hemoglobin concentrations were determined by measuring the absorbance at 415 nm. Sal treatments did not significantly reduce total hemoglobin content. Error bars represent ± SEM of five independent experiments (three unique donors). P values were calculated using an unpaired two-tailed t-test and were found to be non-significant (NS). The P value for 3 μM and 6 μM Sal compared to untreated was P=0.26 and P=0.32, respectively. experiments analyzing GBZ treated cells. P values were determined using a unpaired two-tailed t-test. * P < 0.05; ** P < 0.01.
(C) Differentiating human primary erythroid progenitors were infected with a control shRNA (shCTRL) and shRNAs targeting either GADD34 (shGADD34) or CReP (shCReP) on days 12 and 13. On day 16, transcript levels were evaluated for GADD34 and CReP using qPCR. Both shGADD34 and shCReP resulted in about 50% knockdown when normalized to the shCTRL.
Error bars denote ± SEM of three independent experiments (three different donors).
(D) Western blotting shows shGADD34 and shCReP result in significant knockdown of GADD34 and CReP protein, respectively, in comparison to shCTRL. Protein lysates were taken on day 16 of differentiation after two infections on days 12 and 13. β-Actin was used as a loading control.
(E) Protein lysates were taken on days 16 and 18 of differentiation from erythroid progenitors infected with shCTRL, shGADD34, or shCReP. Western blotting reveals both shGADD34 and shCReP significantly increase p-eIF2α levels compared to shCTRL. β-Actin and total eIF2α were used as loading controls. 
SEM of three independent experiments (three different donors)
. P values were determined using a one sample two-tailed t-test. * P < 0.05; ** P < 0.01. 
